Journal of Gastrointestinal Surgery

, Volume 16, Issue 2, pp 301–311 | Cite as

Surgical Resection Versus Local Ablation for HCC on Cirrhosis: Results from a Propensity Case-Matched Study

  • Andrea Ruzzenente
  • Alfredo Guglielmi
  • Marco Sandri
  • Tommaso Campagnaro
  • Alessandro Valdegamberi
  • Simone Conci
  • Fabio Bagante
  • Gianni Turcato
  • Mirko D’Onofrio
  • Calogero Iacono
2011 SSAT Plenary Presentation



Surgery for hepatocellular carcinoma (HCC) had great improvements in the last decades with low morbidity and mortality and good long-term results. Percutaneous local ablative therapies (LAT) such as radiofrequency ablation and ethanol injection (PEI) for HCC gained consent for their efficacy and safety. In retrospective studies, patients submitted to resection (LR) or LAT frequently have important selection bias. Propensity case-matched analysis proved to reduce selection bias of retrospective studies and allow comparison between different therapies.


The aim of this study was to evaluate survival comparing LR and LAT in two groups of cirrhotic patients with HCC matched with propensity score methods.


Four hundred and seventy-eight cirrhotic patients with HCC treated with LR or LAT with curative intent between January 1995 and December 2009 were included in the study. One hundred and eighty-one patients underwent LR, and 297 patients were treated with LAT. Tumor stage and liver function were evaluated in all patients. To balance the covariates in the two groups, a one-to-one propensity case-matched analysis was used. A multivariable logistic model based on age, gender, etiology of cirrhosis, Child-Pugh class, number of nodules, maximum diameter of nodules, and serum alpha-fetoprotein level was used to estimate propensity score. One-to-one caliper matching of LR and LAT groups was performed, generating a matched sample of 176 patients with 88 patients in each group.


Median survival was 65.1 months (95% CI = 48.5–81.7) after LR and 37.3 months (95% CI = 29.3–45.3) after LAT (p = 0.008). For patients in Child-Pugh class A with single HCC and maximum diameter <5 cm, median survival was 65.0 months (95% CI = 58.4–71.6) for the LR group and 63.7 months (95% CI = 31.8–95.7) for the LAT group (p = 0.730). For patients in Child-Pugh class A with single HCC and diameter ≥5 cm, median survival was 79.9 months (95% CI = 40.1–119.8) for the LR group and 21.5 months (95% CI = 10.8–32.1) for the LAT group (p = 0.023). For patients in Child-Pugh class A with two to three nodules and maximum diameter ≤3 cm, mean survival was 69.3 months (95% CI 48.7–89.9) for the LR group and 45.7 months (95% CI = 22.8–68.7) for the LAT group (p = 0.168). For patients in Child-Pugh class A with two to three nodules and diameter >3 cm, median survival was 82.9 months (95% CI = 52.0–113.7) for the LR group and 18.9 months (95% CI = 6.3–31.4) for the LAT group (p = 0.001).


Our propensity case-matched study confirmed that survival is similar after LR and LAT for single HCC smaller than 5 cm and for oligofocal HCC (up to three nodules) smaller than 3 cm; instead, for HCC larger than 5 cm or oligofocal HCC (up to three nodules) larger than 3 cm, surgical resection improves significantly long-term survival.


Hepatocellular carcinoma Surgery Local ablative therapies Liver cirrhosis 



  1. 1.
    Fan ST, Mau Lo C, Poon RT, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 2011;253:745–58.PubMedCrossRefGoogle Scholar
  2. 2.
    Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001;234:63–70.PubMedCrossRefGoogle Scholar
  3. 3.
    Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol 1996;167:759–68.PubMedGoogle Scholar
  4. 4.
    Guglielmi A, Ruzzenente A, Battocchia A, Tonon A, Fracastoro G, Cordiano C. Radiofrequency ablation of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology 2003;50:480–4.PubMedGoogle Scholar
  5. 5.
    Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008;47:82–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Vivarelli M, Guglielmi A, Ruzzenente A, et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg 2004;240:102–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Guglielmi A, Ruzzenente A, Valdegamberi A, et al. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2008;12:192–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Guo WX, Zhai B, Lai EC, et al. Percutaneous radiofrequency ablation versus partial hepatectomy for multicentric small hepatocellular carcinomas: a nonrandomized comparative study. World J Surg 2010;34:2671–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Yun WK, Choi MS, Choi D, et al. Superior long-term outcomes after surgery in Child-Pugh class A patients with single small hepatocellular carcinoma compared to radiofrequency ablation. Hepatol Int 2010;5:722–729Google Scholar
  10. 10.
    Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010;252:903–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Bruix J SM, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000. J Hepatol 2001;35:421–30.PubMedCrossRefGoogle Scholar
  13. 13.
    Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:14.CrossRefGoogle Scholar
  15. 15.
    Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007;26:734–53.PubMedCrossRefGoogle Scholar
  16. 16.
    Clayton D. A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence. Biometrika 1978;65:10.CrossRefGoogle Scholar
  17. 17.
    Grambsch G, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:11.CrossRefGoogle Scholar
  18. 18.
    Peng ZW, Zhang YJ, Chen MS, Lin XJ, Liang HH, Shi M. Radiofrequency ablation as first-line treatment for small solitary hepatocellular carcinoma: long-term results. Eur J Surg Oncol 2010;36:1054–60.PubMedCrossRefGoogle Scholar
  19. 19.
    Abu-Hilal M, Primrose JN, Casaril A, McPhail MJ, Pearce NW, Nicoli N. Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J Gastrointest Surg 2008;12:1521–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Huang J, Hernandez-Alejandro R, Croome KP, et al. Radiofrequency ablation versus surgical resection for hepatocellular carcinoma in Childs A cirrhotics-a retrospective study of 1,061 cases. J Gastrointest Surg 2011;15:311–20.PubMedCrossRefGoogle Scholar
  21. 21.
    Hong SN, Lee SY, Choi MS, et al. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol 2005;39:247–52.PubMedCrossRefGoogle Scholar
  22. 22.
    Wakai T, Shirai Y, Suda T, et al. Long-term outcomes of hepatectomy vs percutaneous ablation for treatment of hepatocellular carcinoma < or =4 cm. World J Gastroenterol 2006;12:546–52.PubMedGoogle Scholar
  23. 23.
    Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology 2010;78 Suppl 1:113–24.PubMedCrossRefGoogle Scholar
  24. 24.
    Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Kudo M. Local ablation therapy for hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2004;39:205–14.PubMedCrossRefGoogle Scholar
  26. 26.
    Lu DS, Raman SS, Limanond P, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 2003;14:1267–74.PubMedCrossRefGoogle Scholar
  27. 27.
    Lam VW, Ng KK, Chok KS, et al. Incomplete ablation after radiofrequency ablation of hepatocellular carcinoma: analysis of risk factors and prognostic factors. Ann Surg Oncol 2008;15:782–90.PubMedCrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2011

Authors and Affiliations

  • Andrea Ruzzenente
    • 1
    • 3
  • Alfredo Guglielmi
    • 1
  • Marco Sandri
    • 1
  • Tommaso Campagnaro
    • 1
  • Alessandro Valdegamberi
    • 1
  • Simone Conci
    • 1
  • Fabio Bagante
    • 1
  • Gianni Turcato
    • 1
  • Mirko D’Onofrio
    • 2
  • Calogero Iacono
    • 1
  1. 1.General Surgery “A,” Department of SurgeryUniversity of VeronaVeronaItaly
  2. 2.Department of RadiologyUniversity of Verona Medical SchoolVeronaItaly
  3. 3.General Surgery “A,” Department of SurgeryUniversity of Verona Medical School, GB Rossi University HospitalVeronaItaly

Personalised recommendations